The edge of biotech hedge funds: $1,000/hour expert calls and spotting doomed trials

owl_posting · x · 2026-11-21

Works in Progress publishes Abhishaike Mahajan's deep dive into how biotech-focused hedge funds (Baker Brothers, Deerfield, OrbiMed, each managing $15B+) beat the scientists at predicting trial results:

The counterintuitive core: a surprisingly large share of clinical trial outcomes are decently predictable to anyone willing to look.

Original post →

More from Venture

Venture channel →